Usage of SGLT2 inhibitors lead to amelioration of fatty liver, reduction of visceral fat mass, and mitigation of insulin resistance [41,42,43,44,45,46,47] (Figure 2). The gene discussed is SLC5A2; the disease is Insulin resistance.